From Wikipedia, the free encyclopedia
LY3372689
Names
IUPAC name
N -[4-fluoro-5-[[2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]piperidin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide
Identifiers
InChI=1S/C16H22FN5O3S/c1-9-6-12(24-8-14-19-11(3)25-21-14)4-5-22(9)7-13-15(17)20-16(26-13)18-10(2)23/h9,12H,4-8H2,1-3H3,(H,18,20,23)
Key: FRVXHWNHGWUTQO-UHFFFAOYSA-N
CC(NC1=NC(F)=C(CN2CC[C@H](OCC3=NOC(C)=N3)C[C@@H]2C)S1)=O
Properties
C 16 H 22 F N 5 O 3 S
Molar mass
383.44 g·mol−1
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
Chemical compound
LY3372689 is a drug candidate molecule under investigation to treat Alzheimer's disease. It targets the enzyme
O-GlcNAcase .
[1] Its result is to reduce formation of
tau protein tangles.
A molecule containing radioactive fluorine was used with a
PET scan to show that LY3372689 binds in the human brain.
[2]
Eli Lilly and Company is recruiting subjects for a clinical trial.
[3] Some hospitals in Australia:
St Vincent's Hospital, Sydney
Hornsby Ku-Ring-Gai Hospital ,
The Prince Charles Hospital ,
The Queen Elizabeth Hospital, Adelaide ,
Box Hill Hospital , and
Delmont Private Hospital are involved.
[4] Results of the trial are expected by June 2024.
[5]
Chemical
The molecule contains three rings:
thiazole ,
piperidine and
oxadiazole . Other functional groups included are an
ether ,
acetamide , and a
fluoride .
[6]
References
^
"LY3372689" . www.alzforum.org .
^ Shcherbinin, Sergey; Kielbasa, William; Dubois, Susan; Lowe, Stephen L; Phipps, Krista M; Tseng, James; Kevin, Donnelly B; Natanegara, Fanni; Warner, Susan; Dreyfus, Nicolas; Lindsay-Scott, Peter; Hawk, Mai Khanh; McDonald, Nicholas; Zhang, Xiaoyu; Gilmore, Julie A; Biglan, Kevin; Mergott, Dustin J; Russell, David; Gunn, Roger N; Constantinescu, Cristian; Nuthall, Hugh Norman; Collins, Emily C (December 2020).
"Brain target occupancy of LY3372689, an inhibitor of the O-GlcNAcase (OGA) enzyme: Translation from rat to human: Neuroimaging / evaluating treatments" . Alzheimer's & Dementia . 16 (S4).
doi :
10.1002/alz.040558 .
S2CID
227501893 .
^
"Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer's Disease" . clinicaltrials.gov. 22 March 2022. Retrieved 31 March 2022 .
^
"A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease" . Retrieved 31 March 2022 .
^ Krietsch Boerner, Leigh (25 March 2022).
"Hybrid meeting divulges structures of drug candidates" . Chemical & Engineering News .
ISSN
0009-2347 .
^ Dreyfus, Nicolas Jacques Francois; Lindsay-Scott, Peter James (2 August 2018).
"N -[4-Fluoro-5-[[(2S ,4S )-2-Methyl-4-[(5-Methyl-1,2,4-Oxadiazol-3-Yl)methoxy]-1-Piperidyl]methyl]thiazol-2-Yl]acetamide as Oga Inhibitor" . Retrieved 31 March 2022 .